Mikiya Ishihara, Yoshihiro Nishida, Shigehisa Kitano, Akira Kawai, Naozumi Harada, Yoshihiro Miyahara, Hiroyoshi Hattori, Kohichi Takada, Makoto Emori, Shigeki Kakunaga, et al. O16-2 Phase I trial of NY-ESO-1 TCR-T cell therapy combined with nanoparticulate vaccine but without lymphodepletion for STS. Annals of Oncology. 2023. 34. S1391-S1391
Akira Kawai, Mikiya Ishihara, Tomoki Nakamura, Shigehisa Kitano, Shintaro Iwata, Kohichi Takada, Makoto Emori, Koji Kato, Makoto Endo, Yoshihiro Matsumoto, et al. Safety and Efficacy of NY-ESO-1 Antigen-specific T-cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023
Mikiya Ishihara, Yoshihiro Nishida, Shigehisa Kitano, Akira Kawai, Daisuke Muraoka, Fumiyasu Momose, Naozumi Harada, Yoshihiro Miyahara, Naohiro Seo, Hiroyoshi Hattori, et al. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. International journal of cancer. 2023. 152. 12. 2554-2566
Satoshi Okumura, Mikiya Ishihara, Naomi Kiyota, Kimikazu Yakushijin, Kohichi Takada, Shinichiro Kobayashi, Hiroaki Ikeda, Makoto Endo, Koji Kato, Shigehisa Kitano, et al. Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial. BMJ open. 2022. 12. 11. e065109
